Lyman, G. H., Kuderer, N. M., Crawford, J., Wolff, D. A., Culakova, E., Poniewierski, M. S., & Dale, D. C. (2008). Impact of pegfilgrastim on early all-cause mortality in patients receiving cancer chemotherapy. In Journal of Clinical Oncology (Vol. 26, pp. 6552–6552). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2008.26.15_suppl.6552

Lyman, G. H., N. M. Kuderer, J. Crawford, D. A. Wolff, E. Culakova, M. S. Poniewierski, and D. C. Dale. “Impact of pegfilgrastim on early all-cause mortality in patients receiving cancer chemotherapy.” In Journal of Clinical Oncology, 26:6552–6552. American Society of Clinical Oncology (ASCO), 2008. https://doi.org/10.1200/jco.2008.26.15_suppl.6552.

Lyman GH, Kuderer NM, Crawford J, Wolff DA, Culakova E, Poniewierski MS, et al. Impact of pegfilgrastim on early all-cause mortality in patients receiving cancer chemotherapy. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2008. p. 6552–6552.

Lyman, G. H., et al. “Impact of pegfilgrastim on early all-cause mortality in patients receiving cancer chemotherapy.” Journal of Clinical Oncology, vol. 26, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2008, pp. 6552–6552. Crossref, doi:10.1200/jco.2008.26.15_suppl.6552.

Lyman GH, Kuderer NM, Crawford J, Wolff DA, Culakova E, Poniewierski MS, Dale DC. Impact of pegfilgrastim on early all-cause mortality in patients receiving cancer chemotherapy. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2008. p. 6552–6552.